Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22451079 | 0.78 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL21143089 | 0.77 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL10130714 | 0.77 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL23634010 | 0.77 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL15429773 | 0.75 | PIK3CD (0.55) | PIK3CD | |
| SCHEMBL24456873 | 0.75 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL10308833 | 0.75 | PIK3CD (0.55) | PIK3CD | |
| SCHEMBL18391318 | 0.75 | PIK3CD (0.55) | PIK3CD | |
| SCHEMBL23634011 | 0.72 | IDH1 (0.36) | PIK3CD | |
| SCHEMBL23634006 | 0.72 | PIK3CD (0.40) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144836-A1 | NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | BRISTOL-MYERS SQUIBB COMPANY | 2022-05-12 | — | — | US | disclosed |
| US-10550087-B2 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550087-B2 | Process for the preparation of kinase inhibitors and intermediates thereof | MAP3K1, MAP3K6, MAP3K7 | PIK3CD 103/4885 |
| US-20220144836-A1 | NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | CYP2D6, CYP1B1, CYP2B6 | PIK3CD 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.